In a linked commentary, Peter Koulen, Ph.D., of the University of Missouri-Kansas City and colleagues write, “These findings are in accordance with previous work demonstrating aflibercept’s superiority compared with other anti-VEGF treatments in improving functional and anatomical outcomes in DME, particularly in patients with a BCVA of 20/50 or worse.” Read the full article.
